Asset Details
Do you wish to reserve the book?
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease
Do you wish to request the book?
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease
2022
Overview
In type 2 diabetes mellitus (T2DM) and its related disorders like obesity, the abnormal protein processing, oxidative stress and proinflammatory cytokines will drive the activation of inflammatory pathways, leading to low-grade chronic inflammation and insulin resistance (IR) in the periphery and impaired neuronal insulin signaling in the brain. Studies have shown that such inflammation and impaired insulin signaling contribute to the development of Alzheimer's disease (AD). Therefore, new therapeutic strategies are needed for the treatment of T2DM and T2DM-linked AD. Melatonin is primarily known for its circadian role which conveys message of darkness and induces night-state physiological functions. Besides rhythm-related effects, melatonin has anti-inflammatory and antioxidant properties. Melatonin levels are downregulated in metabolic disorders with IR, and activation of melatonin signaling delays disease progression. The aim of this Review is to highlight the therapeutic potentials of melatonin in preventing the acceleration of AD in T2DM individuals through its therapeutic mechanisms, including antioxidative effects, anti-inflammatory effects, restoring mitochondrial function and insulin sensitivity.
Publisher
Ivyspring International Publisher Pty Ltd,Ivyspring International Publisher
Subject
Alzheimer Disease - drug therapy
/ Alzheimer Disease - metabolism
/ Antioxidants - therapeutic use
/ Brain
/ Darkness
/ Dementia
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - metabolism
/ Glucose
/ Humans
/ Insulin
/ Kinases
/ Obesity
/ Review
